Now trading at a price of $65.14, Apellis Pharmaceuticals has moved -2.32% so far today. In contrast, the S&P 500 index moved 0.57%.
Apellis Pharmaceuticals shares moved 56.81% over the last 52 weeks, with a high of $70.75 and a low of $33.32. During this time, the stock outperformed the S&P 500 index by 66.04%. As of January 2022, the company's 50-day average price is $53.0. Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through inhibition of the complement system for autoimmune and inflammatory diseases. The mid-cap Basic Materials company is based in Waltham, MA.
Declining EPS Growth Trend but Improving Debt Levels:
| 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | |
|---|---|---|---|---|
| Revenue (k) | n/a | $250,646 | $66,563 | $75,422 |
| Revenue Growth | n/a | n/a | -73.44% | 13.31% |
| Gross Margins | n/a | 44.38% | -165.57% | -267.48% |
| Gross Margins Growth | n/a | n/a | -473.07% | -61.55% |
| Operating Margins | n/a | -85.27% | -805.67% | -788.38% |
| Operating Margins Growth | n/a | n/a | -844.85% | 2.15% |
| Earnings Per Share | -$4.77 | -$4.53 | -$7.65 | -$5.89 |
| EPS Growth | n/a | 5.03% | -68.87% | 23.01% |
| Free Cash Flow (k) | -$212,828 | -$165,910 | -$564,229 | -$515,269 |
| FCF Growth | n/a | 22.05% | -240.08% | 8.68% |
| Capital Expenditures (k) | $1,693 | $5,422 | $1,103 | $1,524 |
| LT Debt to Equity | 4.17 | 1.75 | 0.95 | 0.55 |
Apellis Pharmaceuticals has negative earnings for the current period, so its trailing twelve month P/E ratio is not meaningful. Its forward P/E isn't meaningful either because its guidance EPS is -3.29.
Apellis Pharmaceuticals's P/B ratio is 17.67 compared to its sector average of 2.08. The company is likely overvalued in terms of its book value.
Apellis Pharmaceuticals Trades Below Its Target Price:
15 analysts are following Apellis Pharmaceuticals and have set target prices ranging from $51.0 to $139.0 per share. On average, they have given the company a rating of buy. At the current price of $65.14, APLS is trading -24.14% away from its average analyst target price of $85.87 per share, implying an analyst consensus of strong upside potential for the stock.
The company has no information on the number of shares sold short since 0.11% of the company's shares are tied to short positions. Institutions own 92% of Apellis Pharmaceuticals's shares, while the insider ownership rate stands at 15%.
